A Retinoid X Receptor Agonist Directed to the Large Intestine Ameliorates T-Cell-Mediated Colitis in Mice.
NEt-3IB
RXR
Th1 cells
colitis
inflammatory bowel disease
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2021
2021
Historique:
received:
27
05
2021
accepted:
29
07
2021
entrez:
3
9
2021
pubmed:
4
9
2021
medline:
4
9
2021
Statut:
epublish
Résumé
Retinoid X receptor (RXR) is a nuclear receptor that heterodimerizes with several nuclear receptors, integrating ligand-mediated signals across the heterodimers. Synthetic RXR agonists have been developed to cure certain inflammatory diseases, including inflammatory bowel diseases (IBDs). However, pre-existing RXR agonists, which are lipophilic and readily absorbed in the upper intestine, cause considerable adverse effects such as hepatomegaly, hyperlipidemia, and hypothyroidism. To minimize these adverse effects, we have developed an RXR agonist, NEt-3IB, which has lipophilic and thus poorly absorptive properties. In this study, we evaluated the effects of NEt-3IB in an experimental murine colitis model induced through the adoptive transfer of CD45RB
Identifiants
pubmed: 34475823
doi: 10.3389/fphar.2021.715752
pii: 715752
pmc: PMC8406631
doi:
Types de publication
Journal Article
Langues
eng
Pagination
715752Informations de copyright
Copyright © 2021 Matsumoto, Takahashi, Watanabe, Nakatani, Takamura, Kurosaki, Kakuta and Hase.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunol. 2017 Mar 15;198(6):2249-2259
pubmed: 28167631
Genes Immun. 2002 Apr;3(2):59-70
pubmed: 11960303
J Immunol. 2013 Oct 1;191(7):3725-33
pubmed: 23980207
Immunology. 2010 Aug;130(4):572-88
pubmed: 20406305
Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E8017-E8026
pubmed: 30072431
Gastroenterology. 2011 Sep;141(3):1014-23
pubmed: 21699791
Endocrinology. 2009 May;150(5):2368-75
pubmed: 19147676
Biol Pharm Bull. 2012;35(4):629-33
pubmed: 22466572
J Immunol. 1989 Feb 1;142(3):760-5
pubmed: 2464024
Arch Dermatol. 2005 Mar;141(3):315-21
pubmed: 15781672
J Biol Chem. 2007 Nov 2;282(44):31882-90
pubmed: 17766241
Endocrinology. 2002 Aug;143(8):2880-5
pubmed: 12130551
Cell. 2008 Jul 11;134(1):97-111
pubmed: 18614014
J Immunol. 2004 May 1;172(9):5790-8
pubmed: 15100326
Arthritis Res Ther. 2013 Apr 17;15(2):R51
pubmed: 23594962
J Immunol. 2010 Mar 15;184(6):2949-57
pubmed: 20173028
Int Immunol. 2019 Mar 28;31(4):251-262
pubmed: 30590577
Int Immunol. 1993 Nov;5(11):1461-71
pubmed: 7903159
J Biol Chem. 2000 Feb 18;275(7):4541-4
pubmed: 10671476
Nat Rev Gastroenterol Hepatol. 2016 Jan;13(1):13-27
pubmed: 26627550
ACS Med Chem Lett. 2015 Jan 20;6(3):334-8
pubmed: 25815156
J Med Chem. 1994 Sep 2;37(18):2930-41
pubmed: 8071941
Int Immunopharmacol. 2006 Aug;6(8):1341-54
pubmed: 16782548
Biochim Biophys Acta. 2009 Jun;1792(6):564-73
pubmed: 19393742
J Immunol. 2002 Mar 15;168(6):2795-802
pubmed: 11884448
Biochem Pharmacol. 1997 Aug 15;54(4):517-24
pubmed: 9313779
Gut. 2004 Sep;53 Suppl 5:V1-16
pubmed: 15306569
Cell. 2014 Mar 27;157(1):255-66
pubmed: 24679540
Int J Mol Sci. 2018 Jul 31;19(8):
pubmed: 30065229
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2288-94
pubmed: 16873729
Therap Adv Gastroenterol. 2015 Nov;8(6):352-9
pubmed: 26557891
PLoS One. 2012;7(9):e46615
pubmed: 23029557
ChemMedChem. 2008 May;3(5):780-7
pubmed: 18297677